Issue Date: July 17, 2017
Sanofi springs for Protein Sciences
Sanofi has agreed to buy Protein Sciences, a vaccines manufacturer, for $650 million. Based in Connecticut, Protein Sciences received FDA approval in October for Flublok Quadrivalent, which it touts as the only recombinant protein-based influenza vaccine to be cleared by the agency. “The acquisition of Protein Sciences will allow us to broaden our flu portfolio with the addition of a non-egg-based vaccine,” says David Loew, head of Sanofi’s vaccines division. Sanofi will pay as much as $100 million more if certain milestones are hit.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society